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Abstract
Background: The diagnosis of atypical non-autoimmune forms of diabetes mellitus, such as maturity onset
diabetes of the young (MODY) presents several challenges, in view of the extensive clinical and genetic
heterogeneity of the disease. In this report we describe a case of atypical non autoimmune diabetes associated
with a damaging HNF1β mutation. This is distinguished by a number of uncharacteristic clinical features, including
early-onset obesity, the absence of renal cysts and diabetic nephropathy. HNF1β-MODY (MODY5) is an uncommon
form of monogenic diabetes that is often complicated by a wide array of congenital morphological anomalies of
the urinary tract, including renal cysts. This report expands on the clinical phenotypes that have been described in
the context of HNF1β mutations, and is relevant as only isolated cases of diabetic nephropathy in the setting of
MODY5 have been reported.
Case presentation: An obese Maltese female with non-autoimmune diabetes, microalbuminuria, glomerular
hyperfiltration, fatty liver and no renal cysts was studied by whole exome sequencing to investigate potential genes
responsible for the proband’s phenotype. A rare missense mutation at a highly conserved site in exon 8 of HNF1β
was identified (c.1580G > A, NM_000458.3, p.Arg527Gln), with multiple in-silico predictions consistent with
pathogenicity. This mutation has not been previously characterised. Additionally, several common susceptibility
variants associated with early-onset obesity, polygenic type 2 diabetes and nephropathy were identified in the
proband that could impose additional effects on the phenotype, its severity or its clinical course.
Conclusion: This report highlights several atypical features in a proband with atypical diabetes associated with an
HNF1β missense mutation. It also reinforces the concept that monogenic causes of diabetes could be significant
contributors to disease burden in obese individuals with atypical diabetes.
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Background
The diagnosis of atypical non-autoimmune diabetes presents
several challenges. These forms of diabetes are best exempli-
fied by maturity onset diabetes of the young (MODY).
MODY is a rare group of genetically heterogenous condi-
tions characterised by beta cell dysfunction and defects in
insulin secretion. Systematic screening of European and
North American paediatric populations has identified a
prevalence range of 1.2 to 4.2% [1–3]. Population-specific
differences in the prevalence of MODY have also been
reported [4, 5].
A wide array of phenotypic heterogeneity is observed
in subjects with different mutations in the various genes
implicated in the pathogenesis of monogenic diabetes, as
this disease can mimic either type 1 or type 2 diabetes
mellitus. Correctly making the diagnosis of MODY is
essential in view of the therapeutic and prognostic impli-
cations. Furthermore, the autosomal dominant pattern
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of inheritance mandates genetic counselling and family
follow-up. The increasing availability of whole exome or
targeted capture followed by high throughput sequen-
cing facilitates the molecular diagnosis of monogenic
diabetes, particularly in cases where the clinical pheno-
type is atypical or complicated by clinical features that
are not routinely associated with MODY. Increasingly,
next generation sequencing followed by interpretation
using publicly-available aggregate exome variant datasets
offers an unrivalled scope for the discovery and annota-
tion of novel variants.
Identifying patients with monogenic diabetes requires
an index of clinical suspicion of the disease followed by
molecular diagnosis to confirm the underlying genetic
defect. Guidelines issued by the International Society for
Paediatric and Adolescent Diabetes (ISPAD) are available
to advise clinicians, and genetic diagnosis is available in
many healthcare systems [6] . Despite these guidelines,
studies have shown that genetic testing for MODY is
under requested and clinical prediction models have
been developed to aid the identification of likely candi-
dates for molecular genetic testing [7, 8].
In this report, we describe a rare damaging missense
mutation in HNF1β that was identified in a proband
with early-onset atypical diabetes with no morphological
renal tract anomalies. The proband had glomerular
hyperfiltration and early stage diabetic nephropathy,
which is unusual in the setting of MODY5. Because of
the unusual features of nephropathy in the absence of
renal cysts and obesity, we performed whole exome
sequencing of the proband.
Methods
Patient
This study was approved by the ethics institutional
review board of the University of Malta (IRB 71/2013).
Written informed consent was obtained from the pro-
band. The mother had demised and the proband’s
brother and father were not available for genetic analysis
at the time of the study.
Sample preparation and whole exome sequencing
Genomic DNA was extracted from a peripheral blood
sample taken from the proband using a QIAamp DNA ex-
traction kit (Qiagen, Hilden, Germany), and checked for
purity and integrity using agarose gel electrophoresis and
UV spectrophotometry. Sample preparation and exon
enrichment for next generation sequencing was per-
formed using a SureSelectXT All Exon V5 kit (Agilent
Technologies, Santa Clara, CA). 3 μg of DNA was
processed according to manufacturer’s instructions. Paired
end sequencing was carried out on an Illumina HiSeq
2500 sequencer (Illumina, Inc., San Diego, CA, USA).
Exome sequencing alignment, variant calling and
mutation detection
Image analysis was performed with the default parame-
ters of Illumina RTA pipeline, and base calling was
carried out using CASAVA. The sequence reads were
mapped and aligned to the Human Reference Genome
(UCSC hg19, NCBI build 37) using the Burrows-
Wheeler transformation algorithm, and duplicated reads
were removed using Picard [9, 10]. FastQC was used to
check the quality of sequence data [11]. Calling of SNPs
and InDels was done using GATK Unified Genotyper,
which uses a Bayesian genotype likelihood model to re-
port alleles and Phred-scaled confidence values [12].
Variants (SNVs and indels) were called with SAMTools,
with reference to public databases including dbSNP and
1000Genomes and gnomAD [13]. Analysis was per-
formed with preference to variants located in genes im-
plicated in atypical non-autoimmune forms of diabetes
and early-onset obesity. The prioritized candidate gene
list was obtained by reviewing publications in PubMed
and OMIM. Analysis focused on non-synonymous
coding variants, frameshift indels, and variants affecting
splice sites, as these are most likely to be pathogenic.
Non-exonic and synonymous variants were excluded
from further analysis. Missense variants were evaluated
for functional impact using a variety of in-silico predic-
tion tools including SIFT [14], Polyphen2 [15], MelaLR
[16], MetaSVN [16], fathmm-MKL [17], DANN [18],
CADD [19], MutationTaster [20], Mutation Assesser
[21] and LRT [22].
Sanger sequencing
Sanger sequencing using standard PCR amplification pro-
cedures was carried out to confirm the selected candidate
variants of interest in the proband and in 300 unrelated
controls of Maltese ethnicity. A 242 base pair region in
exon 8 of HNF1β was amplified using the following for-
ward primer (GGG CTC TGT ACC TGT GTC TT) and
reverse primer (CCA TGG CCT TAT CAC ACC CT)
with an annealing temperature of 54 degrees.
Case presentation
Clinical features
The proband is a 25 year old Caucasian female born
from nonconsanguineous parents of Maltese ethnicity.
She developed obesity in early childhood, with a body
weight at the 97th centile at the age of 9 years. She was
diagnosed with diabetes mellitus at age 11 following her
presentation with osmotic symptoms of hyperglycaemia.
No diabetic ketoacidosis at diagnosis was present, and
both glutamic acid decarboxylase and islet cell anti-
bodies were negative. She was initially treated by diet
and lifestyle changes, and eventually started on metfor-
min during childhood.
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The proband became pregnant at age 21 years, and
she delivered a healthy but macrosomic male infant by
Caesarean section at 35 weeks of gestation weighing 5.
18 kg. Her glycaemic control deteriorated significantly
during pregnancy and was managed by combination
treatment of isophane and soluble insulin. Significant
weight gain also developed during pregnancy, with a
BMI up to 37 kg/m2. Pre-proliferative diabetic retinop-
athy was also present in the proband.
Since pregnancy the proband developed persistent
and significant microalbuminuria (urine microalbumin
> 400 mg/L), leading to macroalbuminuria (albumin-
creatinine ratio > 3000 mg/g) and glomerular hyperfil-
tration (eGFR >170mls/min/1.73m2) with normal
creatinine levels. Urinalysis and urine microscopy
showed no significant findings. Ultra-sonographic
examination of the abdomen revealed normal size and
echotexture in both kidneys, without any signs of ob-
structive uropathy, and normal cortical thickness and
preservation of cortico-medullary differentiation. No
evidence of autoimmune nephropathy or glomerulo-
nephritis was present, with normal ANA, ANCA, C3,
C4, rheumatoid factor IgM, uric acid, C-reactive pro-
tein and serum immunoglobulin levels. The proband
also developed deranged liver function tests, with
moderately elevated gamma glutamyl transferase and
alanine transaminase levels. A viral hepatitis screen
was negative, and hepatomegaly with no focal lesions
and changes of a fatty liver were also evident on
abdominal ultrasound.
As an adult, she is presently overweight (BMI 28 kg/m2)
and glycaemic control is achieved by a combination of
oral hypoglycaemic agents including metformin 1 g tds,
gliclazide 80 mg tds and vildagliptin 50 mg daily. The
proband however shows poor glycaemic control on
combination oral treatment, with HbA1c values around
10%. Her fasting C-peptide concentration at the time of
referral for genetic analysis was 1.4 ng/mL, indicating
endogenous insulin production. Her HOMA-IR at the
time was 2.8 (fasting insulin 5.7 mIU/L, fasting blood glu-
cose 11.05 mmol/l). A repeat fasting C-peptide decreased
to 1.1 ng/mL within 1 year. In addition, the proband was
started on an angiotensin-converting enzyme inhibitor
(perindopril, 8 mg/day) for reno-protection in view of the
proteinuria and gradual increase in blood pressure that
developed in the post pregnancy period. Her blood pres-
sure control is generally well controlled on perindopril.
The proband’s mother had developed diabetes at age
23, and was treated with oral hypoglycaemic agents and
eventually insulin. The father developed type 2 diabetes
aged 68 years, and the proband’s brother developed
diabetes aged 36 years. In addition, three maternal aunts
also had a history of diabetes mellitus. An overview of
the pedigree is shown in Fig. 1.
In view of the above clinical picture, an initial diagno-
sis of early-onset type 2 diabetes complicated by fatty
liver and diabetic nephropathy was made. The case was
subsequently revised when the proband was offered and
consented to genetic analysis for monogenic diabetes. In
keeping with the strong family history of early-onset dia-
betes and the absence of ketoacidosis, the monogenic
diabetes probability calculator showed a high probability
of MODY (> 75.5% positive predictive value) [8]. Whole
exome sequencing was the analytical method of choice,
given the possibility of a primary genetic defect under-
lying the associated obesity, which is an unusual feature
of monogenic diabetes.
Mutation detection
A summary of the mapped sequencing data is shown in
Table 1. WES yielded a total of 118,986 variants, of
which 19,598 were classified as silent mutations, 16,869
as missense variants and 128 as nonsense mutations.
Variants were filtered according to their frequency, loca-
tion, functional consequences and clinical phenotype as
outlined in the methods section.
No nonsense, frameshift, in-frame indels and variants
affecting splicing sites were detected in the proband in
any of the common MODY genes. A heterozygous
missense mutation with predicted damaging effects in
HNF1β was identified in the proband - chromosome 17,
position 36,059,155, c.1580G > A, NM_000458.3, p.
Arg527Gln, exon 8. In-silico analysis of pathogenicity
using various bioinformatic approaches are shown in
Table 2. Clearly, multiple lines of computational evi-
dence provide support for a deleterious effect of this
mutation. Evolutionary conservation analysis also shows
that the p.Arg527Gln mutation occurs at a highly-
conserved position within the protein sequence, and that
this residue is highly conserved across multiple species.
The mutation was confirmed by Sanger sequencing in
the proband (Fig. 2). In addition, the mutation was not
detected by Sanger sequencing in 300 DNA samples of
Maltese ethnicity. In the Genome Aggregation database
(gnomAD), which reports summary data from large-
scale exome and genome sequencing projects, the
HNF1β p.Arg527Gln mutation has a very low frequency
(3/246266, frequency = 0.00001218). This mutation lies
in the C-terminal transactivation domain of the protein,
and is predicted to be likely pathogenic based on the
above criteria.
In addition to mutations in known genes implicated in
monogenic diabetes, we also screened sequence data for
the presence of genomic variants that have been associ-
ated in the literature with other phenotypes present in
the proband, primarily obesity and nephropathy. A sum-
mary of the relevant findings is shown in Table 3.
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Discussion
In the present report, whole exome sequencing revealed
a rare missense mutation in HNF1β that shows high
conservation scores and has in silico predictions in
favour of pathogenicity. This mutation is located in the
C-terminal transactivation domain of HNF1β, is absent
from controls and is present at an extremely low fre-
quency in the Exome Aggregation Consortium dataset.
Furthermore, the proband’s uncharacteristic clinical
phenotype and family history is suggestive of atypical or
monogenic diabetes, although further evaluation of the
mutation is required to provide a conclusive diagnosis of
MODY5 in this case. Multiple prediction algorithms
demonstrate a deleterious effect of this mutation on the
gene. Missense mutations in HNF1β are commonly
associated with both monogenic diabetes and kidney
disease, and a number of in-vitro functional studies have
demonstrated that missense mutations in HNF1β lead to
impaired DNA-binding and reduced transactivation
potential [23–25]. In view of these criteria, the mutation
can be classified as likely pathogenic according to the
established guidelines from the American College of
Medical Genetics and Genomics and the Association for
Molecular Pathology (ACMG/AMP) (criteria PP2, PP2,
PP4, PM1, PM2) [26].
To date, around 230 mutations in HNF1β have been
described [27]. This gene belongs to the homeodomain-
containing family of transcription factors and is involved
in the organogenesis of the kidneys, urinary tract, liver
and pancreas. HNF1β functions as a homo- or hetero-
dimer with a structurally related transcription factor
HNF1α [28]. Mutations in HNF1α are responsible for
the commonest type of monogenic diabetes (MODY3),
characterised by progressive glucose intolerance due to
an insulin secretory defect [7]. In contrast, mutations in
HNF1β are associated with a wide array of clinical
phenotypes that can include renal disease, and which are
distinguished by the absence of clear genotype-phenotype
associations. Primarily, heterozygous mutations in HNF1β
cause a complex Renal cysts and Diabetes syndrome
(RCAD) characterised by early onset diabetes (MODY5),
Fig. 1 Pedigree of the affected family
Table 1 Whole exome sequencing detail of coverage and
number of read
Number of reads in raw sequence 55,723,934
Number of reads after de-duplication 96.63%
Number of mapped reads 99.53%
Number of mapped reads to targeted
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liver dysfunction and pancreatic hypoplasia. The extent
and severity of renal disease varies extensively in HNF1β
mutations, ranging from congenital anomalies of the
kidney and urinary tract (CAKUT), cystic kidneys to
hyperuricaemia [29–31]. HNF1β mutations have been
associated with isolated renal disease in the absence of
diabetes and conversely, HNF1β deletions with young-
onset diabetes but no kidney disease have also been
described [32, 33]. Compared to other MODY genes, a
high rate of de-novo mutations in HNF1β has been
reported in the literature [29]. The variable expressivity of
HNF1β mutations also extends to the type and age of
onset of renal disease, which ranges from intrauterine life
to middle age [34]. A recent multicentre retrospective co-
hort study of patients with HNF1β mutations showed that
stage 3–4 chronic kidney disease was present in 44% of
cases, and end-stage renal disease in 21% of cases [35].
The diabetic phenotype associated with HNF1β mutations
is also equally heterogenous, with severity of glycaemia ran-
ging from impaired glucose tolerance to diabetes requiring
insulin therapy. The mean age of diagnosis of diabetes is
26 years, with a range of 10–61 years [36]. HNF1βmutations
Table 2 In-silico predictors of pathogenicity and evolutionary
conservation analysis for the HNF1βmutation described in the text








PolyPhen-2 - HumVar Probably damaging 0.998
SIFT Damaging 0.038
DAMN score 0.9996
CADD scaled score 35
Evolutionary conservation analysis for HNF1β c.1580G > A (p.Arg527Gln)
Genomic Evolutionary Rate Profiling (GERP) 5.63
PhyloP20way - mammalian 0.935
SiPhy29way - mammalian 0.9297
Fig. 2 a: Excerpt of exome sequencing data visualised with Integrative Genomics viewer. The heterozygous C > T mutation at chromosome 17,
position 36,059,155, in exon 8 of HNF1β is shown in the reverse strand. b: Sanger sequencing trace showing normal [top] and mutated [bottom]
sequence. c: Multiple sequence alignment showing 66 amino acids surrounding the mutation position, indicated by the black box. The amino
acid residue affected is highly conserved across multiple species
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lead to beta cell dysfunction and reduced insulin secretion,
which may be associated with pancreatic hypoplasia [37].
The exact cause of albuminuria and hyperfiltration in
our proband is difficult to ascertain, as no evidence of
renal cystic disease or of CAKUT was present on im-
aging. While renal cystic disease is a major manifest-
ation of HNF1β mutations (65% of cases), considerable
variation in renal phenotype exists. Similarly, studies
have also shown that when renal biopsies are per-
formed there is heterogeneity in the histological diag-
nosis [36]. Despite the presence of diabetes, the renal
dysfunction found in carriers of HNF1β mutations is
thought to be caused by renal development abnormal-
ities rather than diabetic renal disease [38]. However,
the proband also had microvascular complications of
diabetes and poor glycaemic control, making associated
diabetic nephropathy highly probable. A recent case re-
port has described histologically-proven diabetic kidney
disease (DKD) with glomerular sclerosis, severe diffuse
mesangial cell proliferation, matrix expansion and ar-
teriole hyalinosis in a 30 year old female with MODY 5
and macroalbuminuria caused by a missense mutation
in exon 4 of HNF1β [39]. While glomerular hyperfiltra-
tion associated with early onset DM is a powerful risk
factor for the development of progressive diabetic ne-
phropathy, it is more likely attributed to glomerular
DKD in our proband. Interestingly, another case report
has described end-stage renal failure secondary to prob-
able DKD in a patient with HNF1β mutation and
RCAD syndrome [40].
We also examined exome data, focusing on susceptibil-
ity genes for early onset obesity, diabetic kidney disease
and type 2 diabetes mellitus. Several common susceptibil-
ity variants were detected. Presumably, the additive effects
of common risk variants contributes to the presentation,
clinical course and progression of diabetes in the proband.
This report is significant for a number of reasons. Pri-
marily, it expands on the mutational spectrum and wide
array of clinical phenotypes associated with the HNF1β
gene. In the era of personalised medicine, it is increasingly
important to place the clinical phenotype into a gene-
specific context that would enable clinicians to determine
both immediate and future clinical implications to both
the patient and family members. Secondly, it adds to the
few clinical reports that highlight the presence of early-
stage diabetic nephropathy with hyperfiltration due to
probable glomerular DKD in the absence of renal cysts or
renal morphological abnormalities in MODY5. Further-
more, it is important to emphasise that clinicians should
maintain a high index of suspicion for monogenic diabetes
in young onset non-autoimmune disease, and should con-
sider referral for HNF1β mutation analysis in the presence
of renal cysts with or without diabetes. The presence of
obesity from a young age in the proband is also significant,
in view of the fact that the initial diagnosis was of early-
onset type 2 diabetes rather than monogenic diabetes. The
report also reinforces the need for increased research on
the molecular epidemiology of monogenic diabetes in the
Maltese islands. As yet, the prevalence of MODY in Malta
is not determined. It is likely to show significant differ-
ences from studies carried out in northern European pop-
ulations, in part due to strong founder effects that have
been reported on the island [41]. Of note, the same mis-
sense mutation in HNF1β has also been detected in an
unrelated Maltese female referred for monogenic diabetes
screening. The second case involves a 30 year old female
with diabetes since age 13, a family history of paternally-
transmitted early-onset diabetes, a BMI of 26.32 kg/
m2, no history of diabetic ketoacidosis and treatment
with long-acting insulin. Similarly, no renal cysts or
structural renal tract anomalies were identified but in-
vestigation showed microalbuminuria from longstand-
ing diabetes. The identification of the same missense
mutation in two unrelated Maltese probands both
with early-onset diabetes strongly suggests a possible
genetic founder effect for this mutation. The authors
are presently expanding genetic epidemiology studies
to further investigate this.
Table 3 List of genomic variants and their respective minor allele frequency (1000 Genomes, TSI dataset) that have been identified
in the proband
Chromosome Position dbSNP Variant Type Gene Effect MAF Clinical significance
chr3 10,331,457 rs696217 G/T Missense GHRL p.Leu60Met 0.07 Risk factor for metabolic syndrome and childhood obesity
chr6 132,172,368 rs1044498 A/C Missense ENPP1 p.Lys173Gln 0.13 Susceptibility to Insulin resistance
chr4 6,292,915 rs10010131 A/G Intronic WFS1 0.36 Type 2 diabetes risk
chr6 149,721,690 rs237025 G/A Missense SUMO4 p.Val55Met 0.45 Type 2 diabetes risk, diabetic nephropathy
chr13 110,435,231 rs1805097 C/T Missense IRS2 p.Gly1057Asp 0.33 Type 2 diabetes risk
chr11 17,409,572 rs5219 T/C Missense KCNJ11 p.Lys23Glu 0.29 Type 2 diabetes risk
chr6 160,113,872 rs4880 A/G Missense SOD2 p.Val16Ala 0.47 Diabetic nephropathy
chr2 25,141,538 rs11676272 A/G Missense ADCY3 p.Ser107Pro 0.42 Childhood obesity
The variants in this table have been associated with obesity, type 2 diabetes and nephropathy in different studies
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Conclusion
In conclusion, this report has described a rare missense
mutation in exon 8 of HNF1β with multiple in-silico
predictions consistent with pathogenicity. The proband
had childhood onset atypical diabetes complicated by
obesity and early stage diabetic nephropathy in the
absence of renal cysts. The broad phenotypic variability
of both diabetic and renal disease probably accounts for
underdiagnoses of HNF1β mutations in clinical practice.
The authors also emphasise that clinicians should be
vigilant for the possibility of monogenic diabetes even in
obese patients with a strong family history and a high
probability on MODY risk calculators. This is particularly
relevant in specific populations such as in the Maltese
islands, where the population carries high prevalence rates
for both obesity and diabetes, and the genetic epidemiology
of the disease is as yet uncharacterised.
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